{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:34:36Z","timestamp":1790620476253,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T00:00:00Z","timestamp":1657065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T00:00:00Z","timestamp":1657065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>In the absence of head-to-head trials, comprehensive evidence comparing onset of efficacy of novel agents for acute treatment of migraine is lacking. This study aimed to explore the relative efficacy of lasmiditan (serotonin [5-hydroxytryptamine] 1F receptor agonist) versus rimegepant and ubrogepant (calcitonin gene-related peptide antagonists) for the acute oral treatment of migraine through network meta-analysis (NMA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data included in the NMA were identified through a systematic literature search (conducted April 2018, updated May\/December 2020) of phase II\u2013IV, randomised controlled trials (RCTs) in adults with chronic\/episodic migraine with\/without aura. Treatments included: lasmiditan 50, 100, 200 mg; rimegepant 75 mg; ubrogepant 25, 50, 100 mg. Pairwise treatment comparisons from Bayesian fixed-effect\/random-effects NMA, adjusted by baseline risk where appropriate, were conducted. Comparisons were reported as odds ratios with 95% credible intervals. Early-onset efficacy endpoints included: pain freedom at 2 hours and pain relief at 1 and 2 hours. Adverse drug reaction (ADR) profiles were summarised. Heterogeneity and inconsistency in the network were explored; sensitivity analyses investigated robustness of findings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Across 12 RCTs included in the base case, females represented &gt;80% of included patients (mean age 37.9\u201345.7 years). Odds of achieving both pain freedom and pain relief at 2 hours were higher with lasmiditan 100 and 200 mg versus rimegepant 75 mg and ubrogepant 25 and 50 mg. Results for pain relief at 1 hour were consistent with those at 2 hours, but fewer comparisons were available. There were no statistically significant differences between lasmiditan 50 mg and ubrogepant or rimegepant for any outcome. Sensitivity analyses were in the same direction as base case analyses. Most commonly reported ADRs (incidence \u22652%) were: dizziness, fatigue, paraesthesia, sedation, nausea\/vomiting and muscle weakness with lasmiditan; nausea with rimegepant; and nausea, somnolence and dry mouth with ubrogepant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The efficacy findings of this indirect comparison indicate that lasmiditan 100 mg or 200 mg might be an appropriate acute treatment option for patients with migraine seeking a fast onset of action. Differently from rimegepant and ubrogepant, lasmiditan use is associated with mainly neurological events, which are mostly mild or moderate in severity and self-limiting.<\/jats:p><jats:p>350\/350 words<\/jats:p><\/jats:sec>","DOI":"10.1186\/s10194-022-01440-w","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T23:02:19Z","timestamp":1657062139000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings"],"prefix":"10.1186","volume":"23","author":[{"given":"Pepa","family":"Polavieja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Belger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiva Kumar","family":"Venkata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Wilhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,6]]},"reference":[{"issue":"11","key":"1440_CR1","first-page":"954","volume":"17","author":"GBD","year":"2016","unstructured":"GBD (2016) Headache Collaborators (2018) Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17(11):954\u2013976","journal-title":"Lancet Neurol"},{"issue":"2","key":"1440_CR2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s40120-020-00196-2","volume":"9","author":"MJ Doane","year":"2020","unstructured":"Doane MJ, Gupta S, Fang J, Laflamme AK, Vo P (2020) The humanistic and economic burden of migraine in Europe: a cross-sectional survey in five countries. Neurol Ther 9(2):535\u2013549","journal-title":"Neurol Ther"},{"key":"1440_CR3","first-page":"1211","volume":"390","author":"GBD","year":"2016","unstructured":"GBD (2016) Disease and Injury Incidence and Prevalence Collaborators (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390:1211\u20131259","journal-title":"Lancet"},{"issue":"6","key":"1440_CR4","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1177\/0333102419828967","volume":"39","author":"HC Diener","year":"2019","unstructured":"Diener HC, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ, Mandrekar J, International Headache Society Clinical Trials Standing Committee (2019) Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: fourth edition. Cephalalgia 39(6):687\u2013710","journal-title":"Cephalalgia"},{"issue":"7","key":"1440_CR5","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS, Board of Directors of the American Headache Society (2021) The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache 61(7):1021\u20131039","journal-title":"Headache"},{"issue":"1","key":"1440_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/head.13456","volume":"59","author":"American Headache Society","year":"2019","unstructured":"American Headache Society (2019) The American Headache Society Position Statement on integrating new migraine treatments into clinical practice. Headache 59(1):1\u201318","journal-title":"Headache"},{"issue":"21","key":"1440_CR7","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1212\/WNL.0b013e3181a71220","volume":"72","author":"ME Bigal","year":"2009","unstructured":"Bigal ME, Kurth T, Hu H, Santanello N, Lipton RB (2009) Migraine and cardiovascular disease: possible mechanisms of interaction. Neurology 72(21):1864\u20131871","journal-title":"Neurology"},{"key":"1440_CR8","first-page":"271","volume":"83","author":"B Gilmore","year":"2011","unstructured":"Gilmore B, Michael M (2011) Treatment of acute migraine headache. Am Fam Physician 83:271\u2013280","journal-title":"Am Fam Physician"},{"issue":"12","key":"1440_CR9","doi-asserted-by":"publisher","first-page":"4765","DOI":"10.1007\/s12325-020-01494-9","volume":"37","author":"E Leroux","year":"2020","unstructured":"Leroux E, Buchanan A, Lombard L, Loo LS, Bridge D, Rousseau B, Hopwood N, Matthews BR, Reuter U (2020) Evaluation of patients with insufficient efficacy and\/or tolerability to triptans for the acute treatment of migraine: a systematic literature review. Adv Ther 37(12):4765\u20134796","journal-title":"Adv Ther"},{"key":"1440_CR10","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1111\/head.12154","volume":"53","author":"RB Lipton","year":"2013","unstructured":"Lipton RB, Buse DC, Serrano D, Halland S, Reed ML (2013) Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache 53:1300\u20131311","journal-title":"Headache"},{"issue":"Suppl 1","key":"1440_CR11","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1111\/j.1526-4610.2004.04105.x","volume":"44","author":"DW Dodick","year":"2004","unstructured":"Dodick DW, Martin VT, Smith T, Silberstein S (2004) Cardiovascular tolerability and safety of triptans: a review of clinical data. Headache 44(Suppl 1):S20\u2013S30","journal-title":"Headache"},{"issue":"1","key":"1440_CR12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1177\/1756285614562419","volume":"8","author":"U Reuter","year":"2015","unstructured":"Reuter U, Israel H, Neeb L (2015) The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraine. Ther Adv Neurol Disord 8(1):46\u201354","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"1440_CR13","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s10194-017-0807-1","volume":"18","author":"M Deen","year":"2017","unstructured":"Deen M, Correnti E, Kamm K, Kelderman T, Papetti L, Rubio-Beltr\u00e1n E, Vigneri S, Edvinsson L, Maassen Van Den Brink A, European Headache Federation School of Advanced Studies (EHF-SAS) (2017) Blocking CGRP in migraine patients - a review of pros and cons. J Headache Pain 18(1):96","journal-title":"J Headache Pain"},{"issue":"Suppl 2","key":"1440_CR14","first-page":"S23","volume":"25","author":"GL Peters","year":"2019","unstructured":"Peters GL (2019) Migraine overview and summary of current and emerging treatment options. Am J Manag Care 25(Suppl 2):S23\u2013S34","journal-title":"Am J Manag Care"},{"issue":"24","key":"1440_CR15","doi-asserted-by":"publisher","first-page":"e2222","DOI":"10.1212\/WNL.0000000000006641","volume":"91","author":"B Kuca","year":"2018","unstructured":"Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB, COL MIG-301 Study Group (2018) Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study. Neurology 91(24):e2222\u2013e2232","journal-title":"Neurology"},{"issue":"7","key":"1440_CR16","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1093\/brain\/awz134","volume":"142","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK, Gaul C (2019) Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain 142(7):1894\u20131904","journal-title":"Brain"},{"issue":"3","key":"1440_CR17","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1177\/0333102421989232","volume":"41","author":"M Ashina","year":"2021","unstructured":"Ashina M, Reuter U, Smith T, Krikke-Workel J, Klise SR, Bragg S, Doty EG, Dowsett SA, Lin Q, Krege JH (2021) Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study. Cephalalgia 41(3):294\u2013304","journal-title":"Cephalalgia"},{"issue":"5","key":"1440_CR18","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/head.14122","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, Takeshima T, Homma G, Tanji Y, Katagiri H, Komori M (2021) Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients. Headache 61(5):755\u2013765","journal-title":"Headache"},{"issue":"5","key":"1440_CR19","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1474-4422(12)70047-9","volume":"11","author":"M F\u00e4rkkil\u00e4","year":"2012","unstructured":"F\u00e4rkkil\u00e4 M, Diener HC, G\u00e9raud G, L\u00e1inez M, Schoenen J, Harner N, Pilgrim A, Reuter U, COL MIG-202 study group (2012) Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol 11(5):405\u2013413","journal-title":"Lancet Neurol"},{"key":"1440_CR20","unstructured":"Lipton RB, Conway CM, Stock EG, Stock D, Morris BA, McCormack TJ, Frost M, Gentile K, Dubowchik GM, Coric V, Croop R (2018) Efficacy, safety, and tolerability of rimegepant 75 mg, an oral CGRP receptor antagonist, for the treatment of migraine: results from a phase 3, double blind, randomized, placebo-controlled trial, Study 301. Presented at: the 60th Annual Scientific Meeting of the American Headache Society; June 28\u2013July 1, 2018; San Francisco, CA, USA, Abstract 492562"},{"issue":"2","key":"1440_CR21","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1811090","volume":"381","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, Dubowchik GM, Conway CM, Coric V, Goadsby PJ (2019) Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med 381(2):142\u2013149","journal-title":"N Engl J Med"},{"issue":"10200","key":"1440_CR22","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","volume":"394","author":"R Croop","year":"2019","unstructured":"Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, Coric V, Lipton RB (2019) Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet 394(10200):737\u2013745","journal-title":"Lancet"},{"issue":"2","key":"1440_CR23","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1177\/0333102413500727","volume":"34","author":"R Marcus","year":"2014","unstructured":"Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, Fischer TZ (2014) BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia 34(2):114\u2013125","journal-title":"Cephalalgia"},{"issue":"23","key":"1440_CR24","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","volume":"381","author":"DW Dodick","year":"2019","unstructured":"Dodick DW, Lipton RB, Ailani J, Lu K, Finnegan M, Trugman JM, Szegedi A (2019) Ubrogepant for the treatment of migraine. N Engl J Med 381(23):2230\u20132241","journal-title":"N Engl J Med"},{"issue":"19","key":"1440_CR25","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1001\/jama.2019.16711","volume":"322","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Dodick DW, Ailani J et al (2019) Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA 322(19):1887\u20131898","journal-title":"JAMA"},{"issue":"9","key":"1440_CR26","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1177\/0333102416653233","volume":"36","author":"T Voss","year":"2016","unstructured":"Voss T, Lipton RB, Dodick DW, Dupre N, Ge JY, Bachman R, Assaid C, Aurora SK, Michelson D (2016) A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia 36(9):887\u2013898","journal-title":"Cephalalgia"},{"issue":"5","key":"1440_CR27","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1177\/0333102420970523","volume":"41","author":"PJ Goadsby","year":"2021","unstructured":"Goadsby PJ, Blumenfeld AM, Lipton RB, Dodick DW, Kalidas K, Adams A M, Jakate A, Liu C, Szegedi A, Trugman JM (2021) Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications. Cephalalgia 41(5):546\u2013560","journal-title":"Cephalalgia"},{"key":"1440_CR28","first-page":"1","volume":"2","author":"K Johnston","year":"2022","unstructured":"Johnston K, Popoff E, Deighton A, Dabirvaziri P, Harris L, Thiry A, Croop R, Coric V, L'Italien G, Moren J (2022) Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis. Expert Rev Pharmacoecon Outcomes Res 2:1\u201312","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"11","key":"1440_CR29","first-page":"1456","volume":"26","author":"F Agboola","year":"2020","unstructured":"Agboola F, Atlas SJ, Touchette DR, Borrelli EP, Rind DM, Pearson SD (2020) The effectiveness and value of novel acute treatments for migraine. J Manag Care Spec Pharm 26(11):1456\u20131462","journal-title":"J Manag Care Spec Pharm"},{"issue":"10","key":"1440_CR30","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.28544","volume":"4","author":"CP Yang","year":"2021","unstructured":"Yang CP, Liang CS, Chang CM, Yang CC, Shih PH, Yau YC, Tang KT, Wang SJ (2021) Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis. JAMA Netw Open 4(10):e2128544","journal-title":"JAMA Netw Open"},{"issue":"7","key":"1440_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097","journal-title":"PLoS Med"},{"key":"1440_CR32","unstructured":"Centre for Reviews and Dissemination (2009) CRD\u2019s guidance for undertaking reviews in health care. York, England: University of York; 2009. http:\/\/www.york.ac.uk\/inst\/crd\/index_guidance.htm. Accessed 19 Oct 2021."},{"key":"1440_CR33","unstructured":"WebPlotDigitizer Version 4.2 (2019). https:\/\/apps.automeris.io\/wpd\/. Accessed 23 Mar 2022."},{"issue":"9","key":"1440_CR34","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1177\/0333102413485658","volume":"33","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2013","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2013) The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 33(9):629\u2013808","journal-title":"Cephalalgia"},{"key":"1440_CR35","unstructured":"NICE DSU (2022) NICE Decision Support Unit. http:\/\/nicedsu.org.uk\/technical-support-documents\/evidence-synthesis-tsd-series\/. Accessed 23 Mar 2022."},{"issue":"4","key":"1440_CR36","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/10618600.1998.10474787","volume":"7","author":"SP Brooks","year":"1998","unstructured":"Brooks SP, Gelman A (1998) General methods for monitoring convergence of iterative simulations. J Comput Graph Stat 7(4):434\u2013455","journal-title":"J Comput Graph Stat"},{"issue":"7","key":"1440_CR37","first-page":"735","volume":"11","author":"HC Diener","year":"2010","unstructured":"Diener HC (2010) Placebo effects in treating migraine and other headaches. Curr Opin Investig Drugs 11(7):735\u2013739","journal-title":"Curr Opin Investig Drugs"},{"issue":"2","key":"1440_CR38","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti G, Ades AE, Ioannidis JP (2011) Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 64(2):163\u2013171","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"1440_CR39","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1093\/ije\/dys041","volume":"41","author":"RM Turner","year":"2012","unstructured":"Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JP (2012) Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. Int J Epidemiol 41(3):818\u2013827","journal-title":"Int J Epidemiol"},{"issue":"6","key":"1440_CR40","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/sim.6381","volume":"34","author":"RM Turner","year":"2015","unstructured":"Turner RM, Jackson D, Wei Y, Thompson SG, Higgins JP (2015) Predictive distributions for between-study heterogeneity and simple methods for their application in Bayesian meta-analysis. Stat Med 34(6):984\u2013998","journal-title":"Stat Med"},{"key":"1440_CR41","volume-title":"REYNOW (lasmiditan) tablets, for oral use [prescribing information]","author":"Eli Lilly and Company","year":"2021","unstructured":"Eli Lilly and Company (2021) REYNOW (lasmiditan) tablets, for oral use [prescribing information]. Eli Lilly and Company, Indianapolis.\u00a0https:\/\/pi.lilly.com\/us\/reyvow-uspi.pdf. Accessed 23 Mar 2022"},{"key":"1440_CR42","volume-title":"NURTEC ODT (rimegepant) orally disintegrating tablets, for sublingual or oral use [prescribing information]","author":"Biohaven Pharmaceuticals","year":"2020","unstructured":"Biohaven Pharmaceuticals (2020) NURTEC ODT (rimegepant) orally disintegrating tablets, for sublingual or oral use [prescribing information]. Biohaven Pharmaceuticals, Inc., New Haven.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212728s000lbl.pdf. Accessed 23 Mar 2022"},{"key":"1440_CR43","volume-title":"UBRELVY (ubrogepant) tablets, for oral use [prescribing information]","author":"Allergan","year":"2019","unstructured":"Allergan (2019) UBRELVY (ubrogepant) tablets, for oral use [prescribing information]. Allergan USA Inc., Madison.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211765s000lbl.pdf. Accessed 23 Mar 2022"},{"key":"1440_CR44","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1046\/j.1526-4610.2002.0420s1003.x","volume":"42","author":"RB Lipton","year":"2002","unstructured":"Lipton RB, Hamelsky SW, Dayno JM (2002) What do patients with migraine want from acute migraine treatment? Headache 42:S3\u2013S9","journal-title":"Headache"},{"issue":"7","key":"1440_CR45","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1111\/j.1526-4610.2009.01458.x","volume":"49","author":"NT Mathew","year":"2009","unstructured":"Mathew NT, Landy S, Stark S, Tietjen GE, Derosier FJ, White J, Lener SE, Bukenya D (2009) Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache 49(7):971\u2013982","journal-title":"Headache"},{"key":"1440_CR46","doi-asserted-by":"crossref","unstructured":"Atlas S, Touchette D, Agboola F, Lee T, Chapman R, Pearson SD, Rind DM (2020) Acute treatments for migraine: Effectiveness and value. Institute for Clinical and Economic Review, January 8, 2020. http:\/\/icer-review.org\/material\/acute-migraine-evidence-report\/. Accessed 23 Mar 2022","DOI":"10.1016\/j.jval.2020.04.908"},{"issue":"8","key":"1440_CR47","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1177\/0333102419855080","volume":"39","author":"JH Krege","year":"2019","unstructured":"Krege JH, Rizzoli PB, Liffick E, Doty EG, Dowsett SA, Wang J, Buchanan AS (2019) Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: results from SAMURAI and SPARTAN. Cephalalgia 39(8):957\u2013966","journal-title":"Cephalalgia"},{"key":"1440_CR48","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/bs.pbr.2020.06.019","volume":"255","author":"CC Chiang","year":"2020","unstructured":"Chiang CC, Schwedt TJ (2020) Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine\u2013The monoclonal antibodies and gepants. Prog Brain Res 255:143\u2013170","journal-title":"Prog Brain Res"},{"issue":"6","key":"1440_CR49","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1080\/13543784.2019.1618830","volume":"28","author":"A Negro","year":"2019","unstructured":"Negro A, Martelletti P (2019) Gepants for the treatment of migraine. Expert Opin Investig Drugs 28(6):555\u2013567","journal-title":"Expert Opin Investig Drugs"},{"issue":"12","key":"1440_CR50","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1097\/AJP.0000000000000873","volume":"36","author":"N Erpelding","year":"2020","unstructured":"Erpelding N, Evans K, Lanier RK, Elder H, Katz NP (2020) Placebo response reduction and accurate pain reporting training reduces placebo responses in a clinical trial on chronic low back pain: results from a comparison to the literature. Clin J Pain 36(12):950\u2013954","journal-title":"Clin J Pain"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01440-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-022-01440-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01440-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T15:02:49Z","timestamp":1727535769000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-022-01440-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,6]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1440"],"URL":"https:\/\/doi.org\/10.1186\/s10194-022-01440-w","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,6]]},"assertion":[{"value":"15 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors are full-time employees and minor stockholders of Eli Lilly and Company.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"76"}}